CDH3/P-Cadherin regulates migration of HuCCT1 cholangiocarcinoma cells by Baek, Sungmin et al.
Original Article
Corresponding author: 
Sae-Ock Oh
Address: Beomeo-Ri, Mulgeum-eup, Yangsan, Korea [626-870]
Tel: +82-51-510-8045, Fax: +82-51-510-8049, E-mail: hedgehog@pusan.
ac.kr
Th   is is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which 
permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright © 2010. Anatomy and Cell Biology
doi: 10.5115/acb.2010.43.2.110
pISSN 2093-3665   eISSN 2093-3673
CDH3/P-Cadherin regulates migration of 
HuCCT1 cholangiocarcinoma cells
Sungmin Baek
1,2, Yong-Whan Lee
1, Sik Yoon
1, Sun-Yong Baek
1, Bong-Seon Kim
1, Sae-Ock Oh
1,2
1Department of Anatomy, School of Medicine, Pusan National University, 
2Medical Research Center for Ischemic Tissue Regeneration, Pusan National 
University, Yangsan, Korea
Abstract: Intrahepatic cholangiocarcinoma is the second most common subtype of primary hepatobilliary cancer. Despite 
advances in surgical and medical therapy, its survival rate remains poor. Compared to hepatocellular carcinoma (HCC), the 
most common liver malignancy, the underlying mechanisms of cholangiocarcinoma carcinogenesis are poorly characterized. 
P-cadherin (CDH3) is a cadherin super family member. Although CDH3 is frequently over-expressed in cholangiocarcinoma 
tissues, its roles have never been characterized. To determine the roles of CDH3 in cholangiocarcinoma, we investigated CDH3 
function in HuCCT1 cells using specifi  c siRNA. Transfection with CDH3 siRNA did not aff  ect proliferation of HuCCT1 cells. 
However, cell migration and invasion were signifi  cantly reduced when CDH3 was down-regulated. In addition, expressions of 
several biomarkers for epithelial-mesenchymal transition (EMT) were not changed by CDH3 down-regulation. Th  ese  results 
suggest that CDH3 regulates cell migration independent of EMT in cholangiocarcinoma cells. 
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geographic variation in the incidence of cholangiocarcinoma, 
with the highest incidence in East Asia. Th   is high incidence 
is likely due to regional risk factors, such as heptolithiasis and 
liver fl  uke infection. Despite advances in surgical and medical 
therapy, its survival rate is still poor. The main reasons of 
poor prognosis are diagnostic diffi   culty, extensive local tumor 
invasion at diagnosis and multi-drug resistance. 
An important prognostic factor for cholangiocarcinoma 
is metastasis, which precludes curative surgical resection. 
Prognosis is dependent on the presence of free margins in 
resected tissues and the absence of lymph nodes metastasis 
(Olnes & Erlich, 2004). Increased cell invasion and migration 
is a key phenotypic advantage of malignant cells favoring 
metastasis. Several distinct steps have been described in 
the process of metastasis: detachment of tumor cells from 
the primary tumor, invasion into surrounding tissue, 
intravasation into blood or lymphatic vessels, dissemination 
in the blood stream or the lymphatic system, extravasation 
and outgrowth at a secondary site (Yilmaz & Christofori, 
2009). Each of these steps requires a distinct molecular 
Introduction
Cholangiocarcinoma is a malignant tumor originated from 
bile duct epithelial cells (Olnes & Erlich, 2004). Intrahepatic 
cholangiocarcinoma is the second most common subtype 
of primary hepatobilliary cancer (Kato et al., 1990; Taylor-
Robinson et al., 1997; Olnes & Erlich, 2004; Shaib et al., 
2004). Between 1973 and 1997, the incidence and mortality 
rates of intraheptic cholangiocarcinoma in the United 
States was increased by approximately 9%, and is the most 
common primary liver cancer-related cause of death in 
the United Kingdom. The mortality rate of intrahepatic 
cholangiocarcinoma has increased in Japan, Western Europe, 
and Australia between 1979 and 1998. There is significant CDH3 in HuCCT1 cholangiocarcinoma cells
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program. To detach from the primary tumor and invade into 
the surrounding tissue, tumor cells have to break down cell-
cell contacts and the remodel cell-matrix adhesion sites. Th  ese 
processes are known as epithelial-mesenchymal transition 
(EMT). During EMT, non-motile and polarized epithelial 
cells that are usually embedded via cell-cell junctions in a cell 
collective, dissolve their cell-cell junctions and convert into 
individual, non-polarized, motile and invasive mesenchymal 
cells (Yilmaz & Christofori, 2009).
Many EMT biomarkers have been reported (Zeisberg & 
Neilson, 2009). One of most important biomarkers is down-
regulation of E-cadherin. E-cadherin is a cell-cell adhesion 
molecule expressed on the membrane of epithelial cells. 
Moreover, cancer cells undergoing EMT gain mesenchymal 
markers, including N-cadherin, P-cadherin, vimentin, 
collagen 1 and 2. EMT can be prompted by various intrinsic 
signals (e.g. gene mutations) as well as extrinsic signals (e.g. 
growth factor signaling) (Yilmaz & Christofori, 2009). Among 
the growth factors known to induce EMT are transforming 
growth factor β (TGFβ), hepatocyte growth factor (HGF), 
members of the epidermal growth factor (EGF) family, 
insulin-like growth factor (IGF) and fi  broblast growth factor 
(FGF). 
Cadherins (Calcium dependent adhesion molecules) 
are transmembrane proteins which play a role in cell to cell 
adhesion and junction (Takeichi 1995). The majority of 
studies on cadherins have focused on E-cadherin (CDH1) 
and N-cadherin (CDH2). E-cadherin is the prototype family 
member of classical cadherins, single-span transmembrane 
glycoproteins that interact in a calcium-dependent, 
hemophilic manner with E-cadherins on neighboring cells. 
E-cadherin-mediated cell-cell adhesion complexes are 
anchored to the actin cytoskeleton via its cytoplasmic domain, 
β-catenin and α-catenin. N-cadherin also forms hemophilic 
cell-cell adhesion junctions. It is normally expressed in 
nervous tissue, vascular endothelial cells and in skeletal 
and cardiac muscle cells. It is found to be localized in the 
lamellipodia and fi  llopodia. P-cadherin (CDH3) is one of the 
cadherin super family members and fi  rst identifi  ed in mouse 
placenta (Nose & Takeichi, 1986). In human its expression is 
not detectable in the placenta but is present in a few organs, 
such as mammary gland and prostate (Taniuchi et al., 2005). 
Unlike the E- and N-cadherins, CDH3 has not fully been 
investigated and its roles remain unclear. Although previous 
studies have shown that CDH3 was related to various cancers, 
such as breast cancer (Paredes et al., 2005; Paredes et al., 2008; 
Gorski et al., 2009), colorectal cancer (Milicic et al., 2008; 
Hibi et al., 2009a), gastric cancer (Hibi et al., 2009b), head and 
neck cancer (Dasgupta et al., 2006), ovarian cancer (Cheung 
et al., 2010), and pancreatic cancer (Taniuchi et al., 2005; Imai 
et al., 2008), the pathological roles played by CDH3  remain 
poorly investigated. 
Compared to HCC, the underlying mechanisms of 
cholangiocarcinoma carcinogenesis are poorly characterized. 
A previous study showed that CDH3 is frequently over-
expressed in cholangiocarcinoma cells (Obama et al., 2005). 
However its roles in cholangiocarcinoma cells have not yet 
been characterized. Th   e aim of this study was to demonstrate 
the roles CDH3 play in cholangiocarcinoma cells. 
Materials and Methods
Cell culture and transfection
HuCCT1 cell line was purchased from the Health Science 
Research Resources Bank (Osaka, Japan). HuCCT1 cells 
were cultured with RPMI1640, 10% FBS and 1x penicillin/
streptomycin at 37
oC and 5% CO2 incubator. CDH3 siRNA 
(Bioneer, Daejeon, Korea) and scrambled (SCR) siRNA 
(Dhamacon, Lafayette, CO, USA) were purchased. Cells were 
transfected with 100 nM of CDH3 siRNA, or SCR siRNA 
with Dhamafect reagent (Dhamacon, Lafayette, CO, USA) 
in accordance with the manufacturer’s protocol. SCR siRNA 
was used as negative control. Th   e sequences of CDH3 siRNA 
duplex were as follows: 5'-CUC UCU GGA AUG GAA CCU 
U-3', 5'-GAC UGA CCU ACA GUG GAC U-3', and 5'-GUG 
ACA ACG UCU UCU ACU A-3'
Proliferation assay
Four days aft  er transfection of CDH3 siRNA into HuCCT1 
cells in a 96-well plate, 10 ul of Ez-Cytox (ITSBIO, Seoul, 
Korea) were added and incubated for 2 h under normal cell 
culture conditions. Cell viability was measured by absorbance 
at 450 nm using an ELISA reader (TECAN, Mannedorf, 
Switzerland). 
Wound-healing assay
A day after transfection of CDH3 siRNA into HuCCT1 
cells in a 6-well plate, cells were transferred and cultured to a 
48-well plate until confl  uent. Th   ree hours following treatment 
with mitomycin C at 5 μg/ml (Sigma-Aldrich, St. Louis, 
MO, USA), cells were scratched using 200 ul yellow tips and Anat Cell Biol 43:110~117, 2010 Sungmin Baek, et al 112
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changed fresh media to incubate for 22 h.
Matrigel invasion assay
As described by Jeon et al. (Jeon et al., 2010), following a 
day of transfection with SCR or CDH3 siRNA into HuCCT1 
cells, transfected cells were seeded to a 24-well BioCoat
TM 
Matrigel
TM chamber inserts (BD Biosciences, San Jose, CA, 
USA). After 36 h, cells on the inside of the inserts were 
removed with cotton tips, and the invaded cells on the 
outside of the inserts were visualized using hematoxylin/eosin 
staining.
Real-time RT-PCR
Total RNA was extracted using RNeasy Mini kit (Qiagen, 
Valencia, CA, USA) in accordance with the manufacturer’s 
protocol. cDNA was synthesized with MMLV reverse 
transcriptase (Promega, Madison, WI, USA), dNTP and oligo-
dT primers. Real-time RT-PCR was carried out using Power 
SYBR Green PCR Master Mix (Applied Biosystems, Foster 
city, CA, USA) in the ABI Prism 7500 sequence detector 
(Applied Biosystems, Foster city, CA, USA) in accordance 
with the manufacturer’s protocol. Th   e primer sequences were 
as follows: CDH1 (F: 5'-TGG GCC AGG AAA TCA CAT CC-
3', R: 5'-CTC AGC CCG AGT GGA AAT GG-3'), CDH3 (F: 
5'-CCC CCA GAA GTA CGA GGC CCA-3', R: 5'-ACG CCA 
CGC TGG TGA GTT GG-3'), Fibronectin (F: 5'-GAG CTG 
CAC ATG TCT TGG GAA C-3', R: 5'-GGA GCA AAT GGC 
ACC GAG ATA-3'), SNAI1 (F: 5'-GGA CCC ACA CTG GCG 
AGA AG-3', R: 5'-ATT CGG GAG AAG GTC CGA GC-3'), 
SNAI2 (F: 5'-TTG CAA GAT CTG CGG CAA GG-3', R: 5'-
AAT GCT CTG TTG CAG TGA GGG C-3'), Vimentin (F: 5'-
TGA GTA CCG GAG ACA GGT GCA G-3', R: 5'-TAG CAG 
CTT CAA CGG CAA AGT TC-3') and β-actin (F: 5'-CAA 
GAG ATG GCC ACG GCT GC-3', R: 5'-TCC TTC TGC ATC 
CTG TCG GC-3'). β-actin was used as a loading control and 
all signals were normalized to β-actin. 
Western blotting
Transfected cell lysates were run onto 10% SDS-PAGE gel 
and transferred to a PVDF membrane. Blocking was carried 
out with 3% BSA in PBS for 1 h at room temperature. CDH3 
antibody (BD Biosciences, CA, USA) was diluted to 1 : 500 
in 3% BSA in PBS, and incubated overnight at 4
oC. β-actin 
antibody (Abcam, Cambridge, MA, USA) was diluted to 1 : 
2000 in 3% BSA in PBS. HRP-conjugated secondary antibody 
(Jackson ImmunoResearch Laboratories, West Grove, PA, 
USA) was diluted to 1 : 2,000 in PBST and incubated for 2 
h at room temperature. Blots were visualized by enhanced 
chemiluminescence (Amersham Bioscience, Freiburg, 
Germany). 
Data analysis
All data are presented as means±SEM. All experiments 
were repeated at least 4 times. The difference between the 
mean values of two groups was evaluated using the Student’s 
t-test (unpaired comparison). For comparison of more than 
three groups, we used one-way analysis of variance (ANOVA) 
test followed by Tukey’s multiple comparison. A P value of 
<0.05 was considered statistically signifi  cant.
Results
CDH3 is knockdowned through the siRNA 
Prior to investigating CDH3 functions in cholangio-
carcinoma cells using siRNA, we checked whether CDH3 
siRNA specifically down-regulate its expression level. Cells 
Fig. 1. CDH3 siRNA specifically knock-downed CDH3 expression 
level.  48 h following transfection, CDH3 and SCR siRNA-transfected 
HuCCT1 cells were collected and RNA and protein were purified. 
Real-time RT-PCR (A) and Western blotting (B) were performed with 
CDH3 specific primers and antibody. β-actin was used for loading 
control. Data are expressed as percent change (means±SEM) compared 
to control. *P<0.01 (Student’s t-test).CDH3 in HuCCT1 cholangiocarcinoma cells
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were harvested two days after transfection with CDH3 or 
scrambled siRNA. Real-time RT-PCR showed transfection 
of CDH3 siRNA into HuCCT1 cells dramatically decreased 
its mRNA expression level while scrambled control siRNA 
made no impact (Fig. 1A). CDH3 protein level was measured 
by Western blotting using CDH3 antibody. CDH3 siRNA 
significantly reduced its protein level, whereas scrambled 
siRNA did not (Fig. 1B). These results indicate that CDH3 
siRNA could specifically down-regulate CDH3 expression 
level in HuCCT1 cells.
CDH3 has no eff  ect on cell proliferation
Previous reports showed that CDH3 promoter is 
hypomethylated and highly expressed in various cancer cells 
and tissues (Milicic et al., 2008; Hibi et al., 2009a; Hibi et 
al., 2009b). However, the roles of CDH3 in cell proliferation 
are poorly characterized, especially in cholangiocarcinoma 
cells. We therefore carried out cell proliferation assay to 
determine whether CDH3 affects cell proliferation in 
cholangiocarcinoma cells. Different concentration series 
of CDH3 siRNA were transfected into HuCCT1 cells 1 d 
after cell seeding. Following 4 d of siRNA transfection, 
cell proliferation assay was performed as described in the 
Materials and Methods section. As shown in Fig. 2, down-
regulation of CDH3 did not aff  ect cell proliferation, consistent 
with a previous report (Cheung et al., 2010). Th   is data suggest 
that CDH3 plays in other cellular events rather than cell 
proliferation in cholangiocarcinoma cells. 
Cell migration is decreased by CDH3 knockdown
Previous reports showed that CDH3 aff  ects cell migration 
in pancreatic cancer cells (Taniuchi et al., 2005) and ovarian 
cancer cells (Cheung et al., 2010). We hypothesize that CDH3 
regulates cell migration in cholangiocarcinoma cells. In order 
to verify this hypothesis, CDH3 siRNA or scrambled siRNA 
Fig. 2. Cell proliferation is not aff  ected by down-regulation of CDH3 
in HuCCT1 cells. SCR siRNA and diff  erent concentration series (100 
nM, 50 nM, 10 nM, and 1 nM) of CDH3 siRNA-transfected HuCCT1 
cells in a 96-well plate were incubated for 4 d, and MTT assay was 
performed. Data are expressed as percent change (means±SEM) 
compared to control.
Fig. 3. Down-regulation of CDH3 in HuCCT1 cells reduced migration in wound healing assay. Aft  er transfection as described in Materials and 
Methods, HuCCT1 cells were scratched and allowed to migrate up to 22 h. Control = no transfected, SCR = Scrambled siRNA transfected.Anat Cell Biol 43:110~117, 2010 Sungmin Baek, et al 114
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was transfected into HuCCT1 cells, and cell migration was 
examined using wound-healing assay. Fig. 3 shows that down-
regulation of CDH3 decreased cell migration rate in HuCCT1, 
compared to control and scrambled siRNA. To confi  rm this 
data, we conducted matrigel invasion assay, which is a gold 
standard cancer cell migration and invasion assay. As shown 
in Fig. 4, invasion of HuCCT1 cells through the matrigel was 
signifi  cantly reduced when CDH3 was knock-downed. Th  ese 
results are consistent with previous reports (Taniuchi et al., 
2005; Cheung et al., 2010), and suggest that CDH3 positively 
aff  ect cell migration in HuCCT1 cells. 
CDH3 is not related with EMT 
To reveal how CDH3 regulates cell migration in HuCCT1 
cells, we decided to study EMT because it can affect cancer 
cell migration and invasion (Yilmaz & Christofori, 2009). To 
determine whether EMT is involved in the eff  ects of CDH3 
on cell migration, change in expression level of EMT-related 
genes was measured, using real time RT-PCR after CDH3 
knock-down. Fig. 5 shows that the mRNA expression levels of 
mesenchymal markers (snail1, snail2, and vimentin) were not 
signifi  cantly changed. Although the expression level of CDH1 
was increased, there was no change in CDH2 expression 
level during CDH3 knockdown (data not shown). Th  is  result 
implies that CDH3-dependent cell migration may not involve 
EMT.
Fig. 4. Down-regulation of CDH3 in 
HuCCT1 cells reduced invasion in 
Matrigel invasion assay. After trans-
fection as described in Materials and 
Methods, HuCCT1 cells were allowed 
to invade through the matrigel up to 
36 h. Invaded cells were stained with 
hematoxylin/eosin (A) and counted 
to quantify (B). Data are expressed 
as percent change (means±SEM) 
compared to control. *P<0.01 (Student’s 
t-test).
Fig. 5. Expression of EMT-related genes in CDH3-knockdowned 
HuCCT1 cells. RNA was purified from SCR or CDH3 siRNA-
transfected cells and real-time RT-PCR was carried out. After 
normalization to β-actin, data are expressed as percent change 
(means±SEM) compared to control.CDH3 in HuCCT1 cholangiocarcinoma cells
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Discussion
The carcinogenesis of cholangiocarcinoma has been 
poorly characterized compared to HCC. Over-expression of 
CDH3 in patients with cholangiocarcinoma has been shown 
in a previous report (Obama et al., 2005). However, its roles 
in carcinogenesis of cholangiocarcinoma have never been 
examined. In the present study, we show that CDH3 regulates 
migration rather than proliferation in cholangiocarcinoma. 
Metastatic cancers can preclude curative surgical resection 
and results in poor prognosis. Over-expression of CDH3 
was reported to be associated with aggressive character and 
poor prognosis in breast and endometrial cancers (Peralta 
Soler et al., 1999; Gamallo et al., 2001; Stefansson et al., 2004). 
Although over-expression of CDH3 in cholangiocarcinoma 
tissues was reported in an immunohistochemistry study 
(Obama et al., 2005), associations between its expression and 
lymph node metastasis, distant metastasis or gross appearance 
were not observed. It must be emphasized that only 23 tumors 
specimens from patients were analyzed. Further studies 
including more tissues specimens should be conducted. 
Th   ere are controversies surrounding the roles of CDH3 in 
cancer cells migration. CDH3 is known to promote migration 
in pancreatic and ovarian cancer (Taniuchi et al., 2005; 
Cheung et al., 2010). In contrast, in mammary epithelial cells, 
CDH3 inhibited migration (Simpson et al., 2008). When 
Panc-1 cells were stably transfected with full-length CDH3 
cDNA, cell migration was significantly enhanced although 
N-cadherin expression was significantly reduced (Taniuchi 
et al., 2005). In CDH3-overexpressing Panc-1 cells, the 
activities of Rac1 and Cdc42 were significantly increased 
(Taniuchi et al., 2005). Moreover, when OVCAR-3 cells and 
Caov-3 cells were stably transfected with CDH3 cDNA, 
cell migration and invasion were significantly enhanced 
(Cheung et al., 2010). When CDH3 expression was down-
regulated using CDH3 siRNA in these cells, cell migration 
and invasion was significantly reduced. In contrast to these 
results, when CDH3 expression was down-regulated using 
CDH3 siRNA in MCF-10A cells (mammary epithelial cells), 
cell migration was significantly enhanced (Simpson et al., 
2008). Th   is discrepancy may be due to diff  erent roles CDH3 
play, depending on cell type. Another explanation may be 
that MCF-10A cells are non-cancerous cells, whereas Panc-
1, Caov-3, and OVCAR-3 cells are cancerous cells. As such, 
the roles of CDH3 in cancerous cells and non-cancerous cells 
may be diff  erent. In the present study, CDH3 siRNA inhibited 
migration of cholangiocarcinoma cells in two experiments: 
wound healing assay, and matrigel invasion assay. Th  e  results 
suggest that CDH3 in cancerous cells supports cell migration. 
Previous reports suggested possible mechanisms on how 
CDH3 regulates migration of cancer cells. Taniuchi et al. 
showed that p120-catenin was involved in the regulation 
of motility by CDH3 (Taniuchi et al., 2005). P120-catenin 
is found in two forms, one bound to cadherins under the 
plasma membrane and the other in the cytoplasm (Kinch 
et al., 1995; Staddon et al., 1995; Anastasiadis & Reynolds, 
2001). Different types of cadherins regulate cell movement 
by controlling the levels of p120-catenin present in the 
cytoplasmic pool. Taniuchi et al. showed that cytoplasmic 
accumulation of p120-catenin significantly correlated 
with CDH3 levels but not with the levels of E-cadherin or 
N-cadherin (Taniuchi et al., 2005). Diff  erent distribution may 
be due to diff  erent affi   nity of p120 for each classic cadherin. 
Because of the low affi   nity for CDH3, more p120-catenin is 
distributed in the cytoplasm when CDH1 is replaced with 
CDH3 by EMT. In addition, Taniuchi et al. showed that 
activation of Rac1 and Cdc42 by CDH3 was inhibited by 
p120-catenin siRNA, which suggested that p120-catenin 
activated Rac1 and Cdc42 GTPases, which are known 
modulators of actin dynamics essential for cell migration and 
invasion (Yilmaz & Christofori, 2009). 
Another mechanism on how p120-catenin regulates 
cell migration and invasion may involve transcriptional 
repressor Kaiso (van Roy & McCrea, 2005). P120-catenin can 
transfer to the nucleus where it binds to Kaiso. In contrast to 
β-catenin/Tcf-mediated transcriptions, where β-catenin acts 
as transactivator, p120-catenin has no transactivation domain, 
but rather release Kasio from its promoter binding sites, 
thereby activates gene expression by de-repression. However, 
the nature of p120/Kaiso target genes is still poorly defined 
(Yilmaz & Christofori, 2009). 
Cadherins have been shown to play roles in signal 
transduction in addition to their structural roles in adhesion 
and migration (Pece & Gutkind, 2000; Suyama et al., 2002; 
Qian et al., 2004). For example, E-cadherin is associated with 
epidermal growth factor receptor (EGFR), thus activating 
the mitogen-activated protein kinase pathway. N-cadherin 
has also been found to interact with fibroblast growth 
factor receptor (FGFr). Moreover, interaction between 
CDH3 and insulin-like growth factor receptor (IGFRr) has 
been suggested. Furthermore, EMT is regulated by various 
growth factors, including EGF, FGF, HGF and IGF, whose Anat Cell Biol 43:110~117, 2010 Sungmin Baek, et al 116
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signaling is fi  nally transmitted into the nucleus where the key 
transcription factors, such as SNAI1, SNAI2, ZEB1 and ZEB2 
are induced (Th  iery et al., 2009; Yilmaz & Christofori, 2009). 
Th   ese results suggest that a change in CDH3 expression level 
may modulate EMT induced by a certain growth factor. To 
test this hypothesis, we examined change in the expression of 
EMT marker genes following transfection with CDH3 siRNA. 
However, we did not observe consistent changes in EMT 
marker genes expression (Fig. 5). 
Although other EMT marker genes including SNAI1, 
SNAI2, and vimentin were not significantly changed after 
transfection with CDH3 siRNA, the expression of CDH1 
was increased, which may suggest redundancy in the level of 
cadherins (Fig. 5). During EMT in carcinogenesis, cadherin 
switch has been well documented (Zeisberg & Neilson, 2009). 
However, effects of change in the expression of CDH3 on 
other cadherins expression were different in different cells. 
Th   e expression level of CDH1 or CDH2 was not changed by 
over-expression or knock-down of CDH3 in ovarian cancer 
cells (Cheung et al., 2010). Th   e expression level of CDH2 was 
reduced however that of CDH1 was not changed by over-
expression of CDH3 in pancreatic cancer cells (Taniuchi et al., 
2005). 
The roles of cadherins in signal transduction pathway 
indicate that they can regulate proliferation. N-cadherin 
negatively controls osteoblast proliferation and survival via 
inhibition of autocrine/paracrine Wnt3a ligand expression 
and attenuation of Wnt, ERK and PI3K/Akt signaling (Haÿ et 
al., 2009). E-cadherin can negatively regulate, in an adhesion-
dependent manner, ligand-dependent activation of divergent 
classes of receptor tyrosine kinases (RTKs), by inhibiting their 
ligand-dependent activation in association with decreases 
in receptor mobility and in ligand-binding affinity (Qian 
et al., 2004). As such, E-cadherin neutralizing antibody 
inhibited proliferation of MDCK cells. However, according to 
published reports, CDH3 does not regulate cell proliferation, 
although CDH3 is highly expressed in numerous cancer 
tissues (Taniuchi et al., 2005; Milicic et al., 2008; Cheung et 
al., 2010).  In Panc-1 cells, neither over-expression of CDH3 
nor functional-blocking of CDH3 regulated cell proliferation 
(Taniuchi et al., 2005). Moreover, when OVCAR-3 cells and 
Caov-3 cells were stably transfected with CDH3 cDNA, 
cell proliferation was not affected (Cheung et al., 2010). 
Furthermore, the crypt fission rate was not significantly 
increased in CDH3 transgenic mouse that harbored CDH3 
over-expression in the intestinal and colonic epithelium 
(Milicic et al., 2008). Consistent with these results, the present 
study showed that down-regulation of CDH3 did not affect 
proliferation in cholangiocarcinoma cells. 
In summary, CDH3 regulates cell migration through EMT-
independent signaling in cholangiocarcinoma cells. Our data 
will contribute to the development of diagnostic molecular 
markers and therapies against cholangiocarcinoma.
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